Estimates for the prognostic effect of HER2 status were based on an analysis of 10,179 cases collected by the Breast Cancer Association Consortium (BCAC), none of which had been diagnosed after 2004, to ensure that patients did not receive trastuzumab6. Here, ERBB2 is linked to breast cancer.